Amneal Pharmaceuticals (AMRX) – StreetInsider.com Reports
-
Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Ciprofloxacin and Dexamethasone Otic Suspension
-
Amneal Pharmaceuticals (AMRX) PT Raised to $8 at Piper Sandler
-
Amneal Pharmaceuticals (AMRX) April 7.5 calls active
-
Amneal Pharmaceuticals (AMRX) PT Raised to $6.25 at Goldman Sachs
-
Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 5c ; Offers Guidance
-
Amneal Pharmaceuticals (AMRX) Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
-
Amneal Pharmaceuticals (AMRX) PT Raised to $8 at Barclays
-
Amneal Pharmaceuticals (AMRX) Provides Quarterly Guidance
-
Amneal Pharmaceuticals (AMRX) call put ratio 3100 calls to 2 put a focus on June 7.5 calls active
-
Amneal Pharmaceuticals (AMRX) June 7.5 calls active
-
Amneal Pharmaceuticals (AMRX) to Move to Nasdaq
-
Amneal Pharmaceuticals (AMRX) and BIAL Announce U.S. Licensing Agreement for ONGENTYS
-
Amneal Pharmaceuticals (AMRX) PT Raised to $6 at Barclays
-
Amneal Pharmaceuticals (AMRX) PT Raised to $7 at Truist Securities
-
Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 6c ; Offers Guidance
-
Amneal Pharmaceuticals (AMRX) Announces Execution of Binding Term Sheet with Holders of Class B Stock
-
Amneal Pharmaceuticals (AMRX) Announces FDA Approval for Calcium Gluconate Injection
-
Amneal Pharmaceuticals (AMRX) Receives First Product Approval in China
-
Amneal Pharmaceuticals (AMRX) Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
-
Amneal Pharmaceuticals (AMRX) PT Raised to $5 at Piper Sandler
-
Amneal Pharmaceuticals (AMRX) PT Raised to $6 at Truist Securities
-
Amneal Pharmaceuticals (AMRX) PT Raised to $5 at Goldman Sachs
-
Amneal Pharmaceuticals (AMRX) PT Raised to $5 at Barclays
-
Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 9c; raises guidance
-
Amneal Pharmaceuticals (AMRX) Submits Abbreviated NDA to FDA for Three Key Complex Generics
-
Amneal Pharmaceuticals (AMRX) Receives U.S. FDA Complete Response Letter for IPX203
-
Amneal Pharmaceuticals (AMRX) Launches Authorized Generic for Xyrem
-
Amneal Pharmaceuticals (AMRX) Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $3 at Piper Sandler
-
Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 3c; Offers FY23 Guidance
-
Moderna, Xpeng and Uber rise premarket; State Street falls
-
Amneal Pharmaceuticals (AMRX) Reports Prelim Q1 Results, Affirms FY23 Guidance
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $4 at Truist Securities
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $4 at Barclays
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $4 at BMO Capital
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $3 at Goldman Sachs
-
Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 2c
-
Amneal Pharmaceuticals (AMRX) Announces FDA Filing Acceptance of Abbreviated NDA for Naloxone Hydrochloride Nasal Spray, USP, 4mg
-
Amneal Pharmaceuticals (AMRX) Launches RELEUKO in the US
-
Amneal Pharmaceuticals (AMRX) Announces FDA Acceptance of NDA for IPX203
-
Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 5c; Offers FY22 Guidance
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $5 at Truist Securities
-
Amneal Pharmaceuticals (AMRX) Receives FDA Approval for Leuprolide Acetate Injection
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $4 at Goldman Sachs
-
Amneal Pharmaceuticals (AMRX) Misses Q2 EPS by 1c; Offers FY22 Guidance
-
Amneal Pharmaceuticals (AMRX) Appoints Deborah M. Autor to its Board
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $6 at Truist Securities
-
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA (AMRX)
-
Amneal Pharmaceuticals (AMRX) Announces Third Biosimilar FDA Approval of FYLNETRA
-
Amneal Pharmaceuticals (AMRX) on Watch After Kashiv Biosciences Receives FDA Approval Of Fylnetra Injection
Back to AMRX Stock Lookup